Tumor Infiltrating Lymphocytes with Injected IL-2 vs Membrane Bound IL-2

< All comics

Tumor Infiltrating Lymphocytes with Injected IL-2 vs Membrane Bound IL-2

TIL therapies have shown potential for impact across multiple solid tumors. One challenge, however, is the use of IL-2 administration to support TIL function. Our latest #HowCellsWork story illustrates this challenge and potential solutions that could improve patient outcomes.

Posted February 5, 2022 · Follow Us:

< Previous Comic

Next Comic >

All Comics in the Making Cell Therapies Series

Permanent vs Transient Cell Engineering

Traditional cell engineering methods often permanently alter cells. In this #HowCellsWork episode, learn how transient approaches can create powerful therapeutics without permanently changing the cell – potentially broadening disease applicability and reducing long-term safety risks!

Jun 6, 2022

Engineering Trojan Horses for Immune Activation

In this #HowCellsWork episode, learn how AACs can act as messengers, delivering instructions to the immune system on how to identify and attack cancer cells!

Jun 6, 2022

Cell Engineering with mRNA

Therapeutic engineering with mRNA offers many exciting cell reprogramming possibilities. In this #HCW episode, we show how immune cells engineered with mRNA can provide Killer T cells with specific instructions and other capabilities to support an attack on tumors!

Feb 5, 2022

Tumor Infiltrating Lymphocytes with Injected IL-2 vs Membrane Bound IL-2

Feb 5, 2022

Autologous vs Allogeneic Therapies

In this story, we explore some of the fundamental differences between autologous and allogeneic cell therapy manufacturing. The two main cell-sourcing strategies for cell therapy have different trade-offs. Autologous cells reduce the chances of a negative immunological reaction, while allogeneic cells can be more cost-effective.

Sep 29, 2021